SCHEMBL27218893

SCHEMBL27218893

Oc1cc(C(F)(F)F)nc(SCCCc2nc(-c3cccc(C(F)(F)F)c3)no2)n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ S1PR1 P21453 1/20 0.47
▸ TP53 P04637 2/20 0.44
▸ FFAR1 O14842 2/20 0.44
▸ MAPT P10636 2/20 0.43
▸ LMNA P02545 1/20 0.43
▸ NPC1 O15118 1/20 0.43
▸ RAB9A P51151 1/20 0.43
▸ SIRT2 Q8IXJ6 1/20 0.43
▸ HDAC1 Q13547 4/20 0.40
▸ HDAC2 Q92769 4/20 0.40
▸ HDAC8 Q9BY41 3/20 0.40
▸ NR1H4 Q96RI1 1/20 0.40
▸ NPSR1 Q6W5P4 1/20 0.39
▸ ALDH1A1 P00352 2/20 0.39
▸ HSD17B10 Q99714 2/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ TSHR P16473 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ L3MBTL1 Q9Y468 1/20 0.39
▸ CASP3 P42574 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27218682 0.94 S1PR1 (0.45) S1PR1TP53FFAR1MAPTLMNA
SCHEMBL27218694 0.90 HDAC1 (0.49) TP53MAPTLMNANPC1RAB9A
SCHEMBL27218812 0.84 SIRT2 (0.52) TP53MAPTLMNANPC1RAB9A
SCHEMBL31494429 0.80 ALDH1A1 (0.47) TP53MAPTLMNANPC1RAB9A
SCHEMBL27218734 0.80 S1PR1 (0.46) S1PR1TP53FFAR1MAPTLMNA
SCHEMBL27218707 0.78 SMN1; SMN2 (0.48) TP53MAPTLMNANPC1RAB9A
SCHEMBL27218848 0.74 SIRT2 (0.52) TP53MAPTLMNANPC1RAB9A
SCHEMBL27218937 0.73 ALDH1A1 (0.40) TP53MAPTNPC1RAB9AHDAC1
SCHEMBL11919088 0.73 NR1H4 (0.57) S1PR1TP53FFAR1MAPTNPC1
SCHEMBL27218664 0.71 TP53 (0.57) S1PR1TP53FFAR1MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4232448-B1 AGONISTS OF FREE FATTY ACID RECEPTOR 1 AND THEIR USE IN DISEASES ASSOCIATED WITH SAID RECEPTOR Halo Therapeutics Ltd (GB) 2025-05-07 — — EP disclosed
EP-3956323-B1 OXAZOLE AND OXADIAZOLE DERIVATIVES USEFUL AS AGONISTS OF FREE FATTY ACID RECEPTOR 1 Halo Therapeutics Ltd (GB) 2025-03-05 — — EP disclosed
US-20240158382-A1 Agonists Of Free Fatty Acid Receptor 1 And Their Use In Diseases Associated With Said Receptor Halo Therapeutics Ltd (GB) 2024-05-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240158382-A1 Agonists Of Free Fatty Acid Receptor 1 And Their Use In Diseases Associated With Said Receptor FFAR1, FFAR2, FFAR3 S1PR1 56/4885TP53 4635/4885FFAR1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback